DE60224200D1 - Assayverfahren für alzheimer-krankheit - Google Patents

Assayverfahren für alzheimer-krankheit

Info

Publication number
DE60224200D1
DE60224200D1 DE60224200T DE60224200T DE60224200D1 DE 60224200 D1 DE60224200 D1 DE 60224200D1 DE 60224200 T DE60224200 T DE 60224200T DE 60224200 T DE60224200 T DE 60224200T DE 60224200 D1 DE60224200 D1 DE 60224200D1
Authority
DE
Germany
Prior art keywords
alzheimer disease
beta
assay procedure
disease
preclinical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224200T
Other languages
English (en)
Other versions
DE60224200T2 (de
Inventor
David M Holtzman
Ronald Demattos
Kelly R Bales
David J Cummins
Steven M Paul
Audrey Yunhua Jia
Naoya Tsurushita
Maximiliano J Vasques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Eli Lilly and Co
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Eli Lilly and Co
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Eli Lilly and Co, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of DE60224200D1 publication Critical patent/DE60224200D1/de
Application granted granted Critical
Publication of DE60224200T2 publication Critical patent/DE60224200T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
DE60224200T 2001-08-17 2002-08-16 Assayverfahren für alzheimer-krankheit Expired - Lifetime DE60224200T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31322101P 2001-08-17 2001-08-17
US31322401P 2001-08-17 2001-08-17
US313224P 2001-08-17
US313221P 2001-08-17
US33498701P 2001-10-23 2001-10-23
US334987P 2001-10-23
PCT/US2002/026321 WO2003015617A2 (en) 2001-08-17 2002-08-16 Assay method for alzheimer's disease

Publications (2)

Publication Number Publication Date
DE60224200D1 true DE60224200D1 (de) 2008-01-31
DE60224200T2 DE60224200T2 (de) 2008-07-10

Family

ID=27405654

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224200T Expired - Lifetime DE60224200T2 (de) 2001-08-17 2002-08-16 Assayverfahren für alzheimer-krankheit

Country Status (11)

Country Link
EP (1) EP1416965B8 (de)
JP (2) JP4511830B2 (de)
AT (1) ATE381346T1 (de)
CA (1) CA2457145C (de)
CY (1) CY1107901T1 (de)
DE (1) DE60224200T2 (de)
DK (1) DK1416965T3 (de)
ES (1) ES2295401T3 (de)
HK (1) HK1061960A1 (de)
PT (1) PT1416965E (de)
WO (1) WO2003015617A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200202799T3 (tr) 2000-02-24 2003-03-21 Washington University St.Louis AB peptidini sekanslayan insanlaştırılmış antikorlar
DK1944040T3 (da) 2001-08-17 2012-10-29 Univ Washington Analysefremgangsmåde for Alzheimers sygdom
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
EP1480041A1 (de) * 2003-05-22 2004-11-24 Innogenetics N.V. Verfahren zur Voraussage, zur Diagnose und zur vergleichenden Diagnose von Alzheimer
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
AU2006319358B2 (en) 2005-11-30 2012-01-19 AbbVie Deutschland GmbH & Co. KG Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2842967T (pt) 2007-01-18 2017-01-13 Lilly Co Eli Fab beta amilóide peguilado
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2010093001A1 (ja) * 2009-02-13 2010-08-19 国立大学法人大阪大学 アルツハイマー病の診断方法および診断薬
MX2012006512A (es) 2009-12-11 2012-08-17 Araclon Biotech Sl Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides.
CA2796339C (en) 2010-04-15 2020-03-31 Abbott Laboratories Amyloid-beta binding proteins
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
EP2511296A1 (de) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden
IL245703B (en) * 2013-11-20 2022-07-01 Univ Iowa Res Found Methods and preparations for the treatment of amyloid deposits
CN109187981A (zh) * 2018-08-01 2019-01-11 万东山 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用
KR102496845B1 (ko) * 2018-08-08 2023-02-08 서울대학교산학협력단 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE247282T1 (de) * 1992-10-26 2003-08-15 Elan Pharm Inc Verfahren zur identifizierung von hemmstoffe der produktion des beta-amyloidpeptids
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6730778B2 (en) * 1997-12-19 2004-05-04 Pharmacia And Upjohn Company Human sel-10 polypeptides and polynucleotides that encode them
TR200202799T3 (tr) * 2000-02-24 2003-03-21 Washington University St.Louis AB peptidini sekanslayan insanlaştırılmış antikorlar

Also Published As

Publication number Publication date
CA2457145C (en) 2010-12-21
DK1416965T3 (da) 2008-05-05
EP1416965A2 (de) 2004-05-12
WO2003015617A3 (en) 2004-01-29
HK1061960A1 (en) 2004-10-15
PT1416965E (pt) 2008-04-01
EP1416965A4 (de) 2005-11-02
CY1107901T1 (el) 2013-09-04
EP1416965B1 (de) 2007-12-19
ATE381346T1 (de) 2008-01-15
JP4511830B2 (ja) 2010-07-28
EP1416965B8 (de) 2008-02-13
CA2457145A1 (en) 2003-02-27
WO2003015617A2 (en) 2003-02-27
JP2004538477A (ja) 2004-12-24
DE60224200T2 (de) 2008-07-10
ES2295401T3 (es) 2008-04-16
JP5162553B2 (ja) 2013-03-13
JP2010044078A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
CY1107901T1 (el) Μεθοδος προσδιορισμου για ασθενεια alzheimer
EP1944040A3 (de) Assay-Verfahren für Alzheimer
DE60235746D1 (de) Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
DK1351707T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyser
WO2006009702A3 (en) Liver disease-related methods and systems
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE234466T1 (de) Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten
ATE318328T1 (de) Diagnostika und therapeutika für osteoporose
GR3025630T3 (en) Monoclonal antibody against human IgE
DE69834263D1 (de) Diagnostischer test für die alzheimersche krankheit
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
WO2002074322A3 (en) Human growth hormone for treating children with abnormal short stature and kits and methods for diagnosing gs protein dysfunctions
WO2000071081A3 (en) Methods of diagnosis and treatment of meniere disease
ATE473295T1 (de) Nukleotidträger zur diagnose und therapie oraler erkrankungen
FR2837284B1 (fr) Methode de diagnostic serologique in vitro des endocardites infectieuses
DE60208040D1 (de) Anti-ssrp-1 monoklonale antikörper und hybridome zur deren herstellung
CA2151945A1 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: BALES, KELLY R., CLOVERDALE, IN 46120, US

Inventor name: CUMMINS, DAVID J., INDIANAPOLIS, IN 46256, US

Inventor name: PAUL, STEVEN M., CARMEL, IN 46032, US

Inventor name: HOLTZMANN, DAVID M., ST. LOUIS, MO, US

Inventor name: DEMATTOS, RONALD, ST. LOUIS, MO 63108, US

8364 No opposition during term of opposition